Eli Lilly and Company Stock News

INDIANAPOLIS , Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D.

- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LL...

The Trump administration's sweeping tariffs have sent ripples through the healthcare sector in 2025. Last week, the US government locked in pharmaceutical tariffs on the EU at 15%.

Some analysts say Eli Lilly's daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial, orforglipron caused weight loss that missed Wall Street's expectations and came below what Novo Nordisk reported for its oral drug in a separate study.

Congratulations, you've got $50,000 in unexpected cash! Will you buy a new car?

Novo Nordisk and Eli Lilly both declined significantly in the last months. This was mainly caused by efficacy uncertainty, further competition and political headwinds. Despite the sell-offs, I currently think just one of the two is a compelling buy, even offering upside potential of up to 77%.

The Global Industry Classification Standard assigns each stock into a market sector to make it easier for investors to compare companies to their peers and track broader market movements.

Eli Lilly (LLY 0.73%) has been a terrific stock to own over the past 15 years; it has consistently outperformed the broader equities market. However, the drugmaker may not be able to pull that off in 2025, because several setbacks this year have sunk its stock price.